MicroRNAs in Breast Cancer: One More Turn in Regulation

Current Drug Targets
|February 20, 2015
PubMed

Insights

MicroRNAs (miRNAs) are key regulators of gene expression implicated in breast cancer. This review highlights their role in therapy resistance and their potential as biomarkers in liquid biopsies for improved patient management.

Area of Science:

  • Molecular Biology
  • Genetics
  • Oncology

Background:

  • MicroRNAs (miRNAs) are small non-coding RNAs regulating gene expression.
  • Deregulation of miRNAs is linked to various pathologies, including cancer.
  • Altered miRNA levels are observed in human breast cancer compared to normal tissues.

Purpose of the Study:

  • To review the role of miRNAs in breast cancer, focusing on therapy resistance.
  • To discuss miRNAs as potential predictive biomarkers for breast cancer treatment.
  • To summarize the utility of circulating miRNAs in liquid biopsies for diagnosis and monitoring.

Main Methods:

  • Literature review of current research on miRNAs in breast cancer.
  • Analysis of miRNA involvement in mechanisms of therapeutic resistance.
  • Summary of studies on circulating miRNA detection in body fluids.

Main Results:

  • MiRNAs are correlated with breast cancer phenotype, subtype, and therapy response.
  • Mechanisms of miRNA-mediated therapeutic resistance include regulating receptors, drug metabolism, cell cycle, apoptosis, and DNA repair.
  • Circulating miRNAs show promise as biomarkers for breast cancer diagnosis and monitoring.

Conclusions:

  • MiRNAs are crucial in breast cancer pathogenesis and therapy resistance.
  • Circulating miRNAs detected in liquid biopsies represent a new generation of cancer biomarkers.
  • Utilizing miRNAs can significantly improve breast cancer patient management and treatment strategies.

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.4K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.9K
MicroRNAs01:22

MicroRNAs

12.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.2K